Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

328 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-09-30

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The mouth may play an important part in monitoring HIV progression. Mucosal lesions of the mouth are often the first sign of infection and their development in already diagnosed individuals indicates disease progression. In addition, saliva may provide a non-invasive way to track viral load. The purpose of this study is to establish standardized practices for examining the mouth and identifying oral mucosal lesions as well as to establish a correlation of viral load with HIV particles found in saliva.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oral Manifestations of Human Immunodeficiency Virus Infection in High Risk Groups

NCT00004781

HIV Infections Candidiasis, Oral

COMPLETED

The Impact of Oral Health in HIV Patients on Antiretroviral Therapy

NCT04645693

HIV Periodontal Diseases Caries +2 more

ACTIVE_NOT_RECRUITING

Analysis of HIV-1 Replication During Antiretroviral Therapy

NCT00767312

HIV

ENROLLING_BY_INVITATION

Rapid Oral Test for Therapeutic Response in HIV/AIDS Patients

NCT01507142

AIDS/HIV PROBLEM

COMPLETED

The Effects of Illnesses on HIV Levels in the Body

NCT00000900

HIV Infections

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The oral cavity has been found to play an important role in monitoring the progression of HIV infection. The occurrence of specific lesions, mainly oral candidiasis and hairy leukoplakia, is strongly associated with a low CD4 cell count and a higher plasma viral load. Furthermore, even though the prevalence of specific oral lesions like candidiasis, hairy leukoplakia, and Kaposi sarcoma (KS) has been found to be lower among patients on highly active antiretroviral therapy (HAART), other oral lesions such as warts have been found to be more prevalent in this population. In addition, saliva has been shown to harbor viral particles, antibodies, and cytokines, and may represent an easily and noninvasively collected specimen for various diagnostic assays, including early diagnosis of HIV. The purpose of this study is to establish a set of standardized practices for examining and diagnosing oral mucosal lesions and to establish a correlation between the amount of HIV found in the saliva with viral load.

Participants in this study will attend only one screening visit and study visit and will be assigned to one of four groups based on viral load and CD4 count. Group A will consist of participants who have a CD4 count of 200 cells/mm3 or less and a viral load greater than 1000 copies/ml. Group B will be made up of participants who have a CD4 count of 200 cells/mm3 or less and a viral load of 1000 copies/ml or less. Group C participants will have a CD4 count that is greater than 200 cells/mm3 and a viral load that is greater than 1000 copies/ml. Participants making up Group D will have a CD4 count that is greater than 200 cells/mm3 and a viral load that is 1000 copies/ml or less.

All participants will have a medical history taken and blood collected as well as performing a throat wash collection and whole saliva collection. In addition, two oral exams will be performed at the study visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Participants who have a CD4 count of 200 cells/mm3 or less and a viral load greater than 1,000 copies/ml

No interventions assigned to this group

B

Participants who have a CD4 count of 200 cells/mm3 or less and a viral load of 1,000 copies/ml or less

No interventions assigned to this group

C

Participants will have a CD4 count that is greater than 200 cells/mm3 and a viral load that is greater than 1,000 copies/ml

No interventions assigned to this group

D

Participants will have a CD4 count that is greater than 200 cells/mm3 and a viral load that is 1,000 copies/ml or less

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV-1 infection, as documented by any rapid test or licensed ELISA test kit and confirmed by Western blot, HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA
* CD4+ cell count obtained ≤ 60 days prior to study entry
* Plasma HIV-1 RNA levels obtained ≤ 60 days prior to study entry
* If receiving ART, participants must be on same ART regimen for at least 12 weeks immediately prior to study entry
* If study participants are not currently on an ART regimen, they must have not discontinued ART therapy within 30 days prior to study entry
* Ability and willingness of study participant or legal guardian/representative to provide informed consent

Exclusion Criteria

* History of head and/or neck radiation secondary to malignancy
* History of any HIV-1 therapeutic related vaccines
* Use of any systemic anti-fungal in the 90 days prior to entry

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No